Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
"No mention of SNG001 or Synairgen."
Tell me you haven't read it without telling me you haven't read it :-)
Precision Medicine, Stratification, SNG, TopMD, Leading Global Universities..
Looks to be a lot of dots connecting with this one.
https://www.medrxiv.org/content/10.1101/2024.04.15.24305820v2
It's a great question this. I don't know the answer, but something to throw in the mix is Porton Down is very much not a commercial lab. As much as this study was "funded by Synairgen" the UKHSA would have had to decide it was also in their interest/benefit to run the study, along with publishing and presenting the results. Market seems to be a fan of the data :)
Re potential RNS - It would certainly seem very newsworthy that the UK gov is presenting data on SNG001.
However - given the abstract looks to say what has already been shared by the company "sng001 has efficacy vs all covid variants" I don't think we'll necessarily an RNS (unless there is more to the collaboration of course)
“our findings provide new lines of evidence supporting the generality of the notion that type I interferon-neutralizing autoantibodies are preexisting risk factors for life-threatening COVID-19; thus, avoiding the adverse effects of these antibodies should be generally considered when treating COVID-19 patients.”
“Therefore, administering IFN-β at an early stage of SARS-CoV-2 infection may be considered a viable option for effectively inhibiting viral replication"
https://link.springer.com/article/10.1007/s10875-024-01683-z
Oh there was this too
" Then there remains the enigma of the post-viral syndrome (Long COVID or post-acute sequelae of SARS-CoV-2 [PASC]) affecting 3% of the UK population with a range of debilitating symptoms, both organ-specific and less specific. The latter symptoms, which include persistent fatigue, myalgias and arthralgias, post-exertion malaise (PEM), cognitive problems (e.g. "brain fog"), headaches, disrupted sleep and orthostatic intolerance are similar, if not identical to, those experienced in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS),3 a greatly misunderstood multi-system post-viral disorder effecting at least 250,000 adults and children in the UK and 17 million worldwide. Hopefully, understanding the mechanisms behind PASC (including PEM4) will also provide insights into those of ME/CFS, and enable effective therapeutic interventions to be developed for both disorders."
https://onlinelibrary.wiley.com/doi/full/10.1111/resp.14661
Tommy I don't have the time to dig anything up, but there have been a number of papers published over the last year or so stating some long covid is from viral persistence in the macrophages - followed by a rational for treatment w antivirals.
The question is could sng001 "cure" long covid.
https://www.pasteur.fr/en/press-area/press-documents/covid-19-persistence-sars-cov-2-lungs-and-role-innate-immunity#:~:text=%22Yet%20it%20has%20long%20been,adaptive%20NK%20cells)%20and%20destroy
One to two weeks after contracting COVID, the SARS-CoV-2 virus generally becomes undetectable in the upper respiratory tract. But does that mean that it is no longer present in the body? To find out, a team from the Institut Pasteur specialized in HIV, in collaboration with a French public research institute, the Alternative Energies and Atomic Energy Commission (CEA), conducted a study on lung cells in an animal model. The results show not only that SARS-CoV-2 is found in the lungs of certain individuals for up to 18 months after infection, but also that its persistence appears to be linked to a failure of innate immunity (the first line of defense against pathogens). This research was published in the journal Nature Immunology on November 2, 2023.
DD
I agree those two cohorts seem the most likely, but there are also "long term viral shedders" and "viral persistence" which have both been noted by the company at the AGM - how and if those two fit in to the two planned trials they have rns'd is a question I don't know the answer to.
That said - Looking at some of the recent science on long covid and viral persistence in the lungs, this could well be something the company are looking to take on.
When reading the below statement:
"“The Company’s cash resources are sufficient to cover its plans to design and establish data from an observational study and two investigator-led/Synairgen-sponsored Phase 2 clinical trials, including manufacture of active and placebo for use in these trials”
It is worth also considering that these look to be standard requirements for many of the platform trials and non dilutive funding/grants
@casanova_lab
"10/ Having now tested more than 40,000 uninfected individuals from the general population, we show that auto-Abs neutralizing IFNα2 carry a higher risk of severe COVID-19, both in children and adults. "
https://twitter.com/casanova_lab/status/1743046537507176628?t=1bvWcEJKSAZWbiclLDL12g&s=19
Thanks for the updated link to the patent Jint.
Can second your recollection from the AGM re tests + Casanova + unknown partner
We still haven't seen auto abs data from Universal - curious if this is the test they have been using